Antiviral Research Journal Citation Rate 2026
0166-3542
eISSN 1872-9096
Elsevier BV
NL
Q1 Quartile Established Impact
About Antiviral Research
Antiviral Research (AR) is a peer-reviewed academic journal covering Cytomegalovirus and herpesvirus research and HIV Research and Treatment, published by Elsevier BV in NL, catalogued under ISSN 0166-3542 (e-ISSN 1872-9096). As of 2026, it has a 2025 2-Year Citation Rate (OpenAlex) of 3.67 (Q1 quartile) — the average number of citations its recent articles received over a two-year window, computed from OpenAlex open citation data, not the Clarivate (JCR) Impact Factor. It operates a subscription model (APC ~$3730 USD). OpenAlex records 9,339 works and 239,672 citations, with an h-index of 178.
Antiviral Research Citation Rate 2026 — In Context
Antiviral Research has a 2025 2-Year Citation Rate (OpenAlex) of 3.67, placing it in the Q1 quartile within the Cytomegalovirus and herpesvirus research research area. This is the average number of citations the journal's recent articles received over a two-year window, computed from OpenAlex open citation data — not the Clarivate (JCR) Journal Impact Factor.
Antiviral Research operates a subscription-based publishing model — readers access articles through institutional subscriptions or pay-per-view.
Researchers looking to publish in Antiviral Research should review the journal's submission tips and verify the latest indexing status against Scopus, DOAJ, and Web of Science using our indexing tracker. To compare Antiviral Research against similar journals in the field, use our journal comparison tool.
Submission Tips for Antiviral Research
- Budget $3730 for the Article Processing Charge. Check if your institution or funder covers OA fees.
- This journal covers Cytomegalovirus and herpesvirus research, HIV Research and Treatment, HIV/AIDS drug development and treatment. Ensure your manuscript aligns with these scope areas to avoid desk rejection.
How Antiviral Research Compares
Compared against 15 journals in the same research areas.
| ISSN (Print) | 0166-3542 |
|---|---|
| ISSN (Online) | 1872-9096 |
| Publisher | Elsevier BV |
| Country | Netherlands |
| APC / Cost | $3730 USD |
In-depth profile & metrics
Antiviral Research is published by Elsevier BV and based in Netherlands. It runs on a subscription or hybrid model with an article-processing charge of USD 3730.
In our subject taxonomy, Antiviral Research is classified under Cytomegalovirus and herpesvirus research, HIV Research and Treatment, HIV/AIDS drug development and treatment and Hepatitis C virus research.
Antiviral Research is indexed in OpenAlex. OpenAlex tracking provides an open, citable record of its output even where commercial indexing is absent.
Its most recent citation rate stands at 3.670.
Research Areas
Links
Continue on JournalsHub
Put what you just read into practice with these free tools.
Frequently Asked Questions about Antiviral Research
Live Indexing Status
Updated April 2026Track real-time indexing metrics to ensure this journal meets your academic requirements.
Citation Rate
Historical Trend
Initial data points onlyCitation Rate by Year
| Year | Value | Source |
|---|---|---|
| 2025 | 3.670 | 2-Year Mean Citedness (OpenAlex) |
Metrics are sourced from OpenAlex, DOAJ and Scopus and reflect the latest data we hold. The headline figure is a 2-year citation rate (OpenAlex), not a Clarivate Impact Factor. Always verify against the journal's official site before relying on it. See our Methodology or report a correction.
Compare Journals
Compare Antiviral Research against similar publications in its field:
Related Journals in Your Field
-
Cell Host & Microbe Elsevier IF 64.50
-
EBioMedicine Elsevier BV IF 8.28
-
Retrovirology BioMed Central IF 4.76
-
PLoS Pathogens Public Library of Science IF 4.54
-
Liver International Wiley IF 3.95
Explore More Journals
Metadata
Last updated: Apr 24, 2026
Updated by: openalex_bulk
OpenAlex ID: S137372404
Get weekly updates for Cytomegalovirus and herpesvirus research journals
Free. Monday morning. New citation rates, CFPs, indexing alerts, predatory watch list. One-click unsubscribe.